Proteasome inhibition by bortezomib: A left hook and a right punch  by Roelofs, Jeroen
EBioMedicine 2 (2015) 619–620
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryProteasome inhibition by bortezomib: A left hook and a right punchJeroen Roelofs
Molecular, Cellular, and Developmental Biology Program, Division of Biology, Kansas State University, 336 Ackert Hall, 1717 Claﬂin Road, Manhattan, KS 66506, United StatesBortezomib (a.k.a. as velcade or PS-341) is used in the clinic to treat The work by Pitcher et al. starts with the observation that challeng-
multiple myeloma (MM) and mantle cell lymphoma (Dou and Zonder,
2014). In addition to the pharmacokinetic properties of the drug, the ef-
fectiveness of the bortezomib depends largely on the difference in
drug sensitivity of the target (cancer) cells compared with other
cells in the body. For bortezomib this is particularly relevant as it tar-
gets a protein complex that is essential for life in all cells. Thus, it is of
fundamental importance to understand why different cells show dif-
ferent levels of sensitivity to this drug. The work presented in this
issue of EBioMedicine by Pitcher et al. (2015–in this issue), provides
a new and intriguing explanation for the exquisite sensitivity of mul-
tiple myeloma cells to bortezomib.
Bortezomib targets one of three active sites of the proteasome.
This was already known before it was developed as drug and has
been conﬁrmed through crystallization studies, showing in molecu-
lar detail that bortezomib interacts with the chymotrypsin-like ac-
tive site in the proteasome, subunit PSMB5 (Borissenko and Groll,
2007). Proteasomes are important for the degradation of short-
lived proteins in the cell. As a consequence proteasome activity is
crucial formany cellular processes, ranging from cell cycle regulation
to signal transduction pathways and from DNA repair to antigen pre-
sentation by MHC class I. Despite a wealth of knowledge concerning
these different aspects, we still don't understand why low levels of
proteasome inhibitor are lethal for MM cells, whereas other cells
are much more tolerant of proteasome inhibitor. One early rationale
was that MM cells depend more than other cells on the NF-κB path-
way, where IκBα needs to be degraded by the proteasome. However,
this does not explain the difference in sensitivity (Hideshima et al.,
2009). An alternative explanation is that the proteasome in MM
cells has a much higher workload as compared with other cells
(Bianchi et al., 2009). As a result modest inhibition would directly
be detrimental for this cell type, while other cell types can buffer this re-
duced capacity. Neither these, nor other explanations put forward so
far, have been fully satisfying in light of published literature (Dou and
Zonder, 2014; Kubiczkova et al., 2014). Identifying the factors that con-
tribute to the differences in sensitivity is important, as it would greatly
facilitate drug development as well as help understand and predict pa-
tient responses to bortezomib treatment for MM and other cancers.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.016.
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causes an almost complete inhibition of proteasome activity, as mea-
sured with the peptide substrate LLVY-amc. Control cell lines, to
which 10 nM bortezomib is not lethal, showed a substantial higher
level of remaining proteasome activity. Thus, the mechanism responsi-
ble for severe inhibition might provide important clues towards the
speciﬁcity and efﬁcacy of proteasome inhibitor drugs.
The observed severe inhibition in MM cells is surprising, because
lysing the cells prior to treatment with the same concentration of
bortezomib only resulted in a 40% reduction in activity. After eliminat-
ing potential trivial explanations, the authors reach the conclusion
that speciﬁcally in living cells proteasome inhibitor treatment results
in some indirect enhanced inhibition. The authors identify changes in
a post-translational modiﬁcation for several proteasome subunits. This
modiﬁcation, which remains to be fully characterized, has previously
been reported by the same group (Pitcher et al, 2014). It appears to be
mainly nuclear, have unusual biochemical properties, and similarities
to ADP ribosylation. As the modiﬁcation remains somewhat elusive,
manipulating the levels of modiﬁcation to determine its effect on pro-
teasome activity is difﬁcult. Nevertheless, the authors show that a spe-
ciﬁc treatment (venomphosphodiesterase-1with S1 nuclease) changes
the modiﬁcation on some proteasome subunits in vitro. This change
correlated with reduced proteasome activity. Summarizing these re-
sults, it suggests that treating cells with proteasome inhibitor has two
effects. First, there is a direct inhibition resulting from inactivation of
proteasome active sites. Second, there is an indirect inhibition, where
bortezomib induces post-translational modiﬁcations on the protea-
some that reduce proteasome activity.
This intriguing newmodel raises awhole set of newquestions.What
is the identity of the post-translational modiﬁcation andwhat is the en-
zyme responsible? Are these more abundant in MM cells as compared
with cells that are more resistant to bortezomib treatment? Identifying
them would allow researchers to rigorously test the model by showing
that cells are less sensitive to bortezomib upon elimination of the mod-
iﬁcation. Furthermore, it will allow researchers to test if this inhibitory
proteasome modiﬁcation is induced or increased speciﬁcally in cells
sensitive for proteasome inhibitors. From a biochemical perspective, it
is interesting that the presence of a proteasome inhibitor buried within
the large enzyme can result in activation of an enzyme responsible for
post-translational modiﬁcations. It has previously been shown that pro-
teasome inhibitors induce structural changes in the proteasome-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ger the recognition by enzymes responsible for the post-translational
modiﬁcation; however, this link between structural changes and induc-
tion of post-translational modiﬁcations remains to be shown.
One problem with bortezomib treatment in the clinic is the oc-
currence of drug resistance, for example through mutation in the
bortezomib binding subunit PSMD5 (Dou and Zonder, 2014). However,
not all causes of resistance have been determined. If patients acquire
mutations that interfere with the ability to induce indirect inhibition
as described here (Pitcher et al., 2015–in this issue), it would be predict-
ed to cause resistance to bortezomib. Besides bortezomib, there are new
proteasome inhibitor drugs under development, like the FDA-approved
second generation proteasome inhibitor carﬁlzomib, for treating
bortezomib-resistant patients and patients experiencing severe
bortezomib-related side effects and toxicity (Dou and Zonder, 2014;
Kubiczkova et al., 2014). It will be important to determine the extent
to which the phenomena described by Pitcher et al. are speciﬁc for
bortezomib, chymo-trypsin-like inhibitors, or all proteasome inhibitors.
In sum, the data by Pitcher et al. suggest that the presence of a strong
indirect inhibition of proteasomes, as seen for MM cells, contributes to
it's ability to speciﬁcally kill MM cells and not healthy cells. If the post-
translational modiﬁcations on the proteasome as described in this
paper are responsible for the severe inhibition, the identiﬁcation of
the enzymes that modulate this modiﬁcation will be interesting new
drug targets to enhance effectiveness of proteasome inhibitors for vari-
ous cancers.
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